ArticleTranslational andrology and urology2026
Disease stage-dependent expression of ADC-related biomarkers in urothelial carcinoma.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biomarker-driven therapies have expanded treatment options for advanced urothelial carcinoma (UC), making reliable assessment of therapeutic targets increasingly important for patient selection and treatment sequencing. The aim of this study was to evaluate the expression of clinically relevant biomarkers [Trop2, HER2/neu, Nectin-4, and programmed death-ligand 1 (PD-L1)] across normal urothelium (NT), primary tumors (PT), and lymph node metastases (LNM) in UC, and to explore their potential implications for biomarker-guided therapy. Methods: Tissue samples from PT (n=157), NT (n=69), and LNM (n=51) were analyzed by immunohistochemistry using established scoring systems [combined positive score (CPS), H-score, immunohistochemical (IHC) score]. Statistical analyses included paired comparisons, correlation analyses, and survival analyses with Kaplan-Meier, and Cox regression. Results: PD-L1 expression was overall low but significantly higher in PT and LNM compared to NT (PT: P=0.001; LNM: P<0.001). Nectin-4 showed low to moderate membranous expression without significant differences across tissue types (P=0.68) and no prognostic impact. Trop2 expression was significantly higher in NT compared to PT and LNM (P<0.001) and was not associated with survival. HER2/neu expression was significantly increased in LNM compared to PT and NT (P<0.01), and was associated with advanced nodal and metastatic stage. No significant co-expression patterns were observed among the four biomarkers. Conclusions: PD-L1, Nectin-4, Trop2, and HER2/neu show heterogeneous and largely independent expression across disease stages in UC, supporting individualized biomarker assessment and highlighting the potential relevance of metastatic tissue sampling for therapy guidance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.